secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2026-11-10T21:15:23+00:00
Accession:  0001104659-26-125188
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

NextCure Q3 net loss $6.8M; Avere merger financing grows to $820M, stockholder vote set for Dec 9
--------------------------------------------------------------------------------

- Financing commitments supporting Avere merger rise to ~$820M: prior $320M concurrent private placement plus a new $500M placement; ~$266M satisfied by canceling Avere convertible notes.
- Special stockholder meeting set for Dec 9, 2026 (record date Nov 3); S-4 declared effective Nov 6, 2026; combined company expected to trade on Nasdaq as AVRX.
- Q3 net loss $6.8M vs $8.6M a year ago; R&D $4.5M (-$1.6M YoY), G&A $4.4M (+$1.6M on $1.8M of merger legal fees), restructuring net gain $2.0M.
- Cash and marketable securities $8.7M at Sept 30, 2026, down $33.1M from $41.8M at Dec 31, 2025; $35.2M used in operations, offset by $1.2M ATM proceeds.
- Delaware Chancery final order Nov 2, 2026 validated July 2025 reverse split; LNCB74 IND transferred to LigaChem Oct 6; legacy holders to receive CVRs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926125188/0001104659-26-125188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926125188/nxtc-20261110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-125188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer